Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Macugen gets favorable review

FDA's Dermatologic and Ophthalmic Drugs advisory committee gave a favorable review to an NDA from Eyetech (EYET) and partner Pfizer

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE